Resiquimod

Small molecule

Also known as EIK1001

Phase 2/3underway

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational readout pending

No completed mid-stage readout is on record. ClinicalTrials.gov estimates the registrational readout at 2035-12-31; company guidance (Eikon Therapeutics, stated 2026-11-12): interim data expected second half of 2027. The sponsor reported topline results of the Phase 2 portion on 2026-05-30 (EIK1001-005 (NCT06246110) Phase 2 data at ASCO 2026: ORR 63.1%); that is not the registrational readout.

Also in development:Melanoma · Phase 2/3

Source for the program status

Company guidance: interim data expected second half of 2027 (NCT07365319; Eikon Therapeutics, 12 Nov 2026). “We announced the first patient had been dosed in TeLuRide-008 in July 2026 and currently anticipate a first prespecified iDMC interim analysis to select a dose for Part 2 of the trial will take place in the second half of 2027.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2/3 (2)
Melanoma
Non-Small Cell Lung Cancer
Phase 2 (9)
Non-Small Cell Lung Cancer
NCT06246110 · Eikon Therapeutics
2024-02-06 – 2027-12 · NSCLC
What this study did
Other / comorbidity
NCT01204684 · Jonsson Comprehensive Cancer Center
2010-10-08 – 2024-08-21 · Glioma, Anaplastic Astrocytoma, Anaplastic Astro-oligodendroglioma, Glioblastoma
What this study did
NCT01583816 · Spirig Pharma Ltd.
2012-05 – 2014-06 · Actinic Keratosis
What this study did
NCT00116662 · Graceway Pharmaceuticals, LLC
started 2005-03 · Warts
What this study did
NCT00117871 · Graceway Pharmaceuticals, LLC
started 2004-10 · Warts
What this study did
NCT00117923 · Graceway Pharmaceuticals, LLC
started 2004-08 · Warts
What this study did
NCT00115141 · Graceway Pharmaceuticals, LLC
started 2004-04 · Warts
What this study did
NCT00114920 · Graceway Pharmaceuticals, LLC
started 2004-03 · Warts
What this study did
NCT00116675 · Graceway Pharmaceuticals, LLC
2005-03 – 2006-04 · Warts
What this study did
Phase 1/2 (5)
Melanoma
NCT02126579 · Craig L Slingluff, Jr
2014-05-01 – 2021-05-05 · Melanoma, Metastatic Melanoma, Mucosal Melanoma
What this study did
Other / comorbidity
NCT01676831 · Abramson Cancer Center at Penn Medicine
2012-02 – 2015-09-28 · Cutaneous T Cell Lymphoma
What this study did
NCT00948961 · Celldex Therapeutics
2009-09 – 2014-02 · Advanced Malignancies
What this study did
NCT01808950 · Spirig Pharma Ltd.
2013-02 – 2013-08 · Nodular Basal Cell Carcinoma
What this study did
NCT00175435 · University of British Columbia
2005-08 – 2007-04 · Hepatitis B
What this study did
Phase 1 (6)
Melanoma
NCT01748747 · Mayo Clinic
2012-10 – 2017-03-30 · Recurrent Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
What this study did
Other / comorbidity
NCT04196530 · Eikon Therapeutics
2019-11-21 – 2024-08-15 · Tumor, Solid
What this study did
NCT03486301 · Eikon Therapeutics
2018-02-15 – 2024-04-30 · Tumor, Solid
What this study did
NCT00821652 · Nina Bhardwaj
2009-02 – 2014-12 · Tumors
What this study did
NCT01737580 · University of British Columbia
2013-04 – 2013-06 · Influenza Vaccination in Seniors
What this study did

Competitive landscape

This drug's own stage for Melanoma: Phase 2/3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Resiquimod: this drugPhase 2/3Small moleculeToll-like receptor 7 and 8 (TLR7/8)not yet gradedNo reviewed efficacy summary in this indication
Aldesleukin (Proleukin)ApprovedRecombinant Cytokine (il-2)Interleukin-2 receptor (IL-2R)not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BinimetinibApprovedSmall moleculeMEK1/2Partial signal
NCT01763164: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)): Binimetinib (MEK162) 2.83 Months (95% CI 2.76 to 3.55) | Dacarbazine 1.51 Months (95% CI 1.48 to 1.71)
CobimetinibApprovedSmall moleculeMEK1/2Reliable signalNo reviewed efficacy summary in this indication
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Reliable signal
NCT01597908: Overall Survival (OS) (From the date of randomization until date of death due to any cause (up to approximately 6 years)): Dabrafenib Plus Trametinib 26 Months (95% CI 22.1 to 33.8) | Vemurafenib 17.8 Months (95% CI 15.6 to 20.7)
NCT01584648: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)): Dabrafenib + Trametinib 10.2 Months (95% CI 8.1 to 12.8) | Dabrafenib + Placebo 8.8 Months (95% CI 5.9 to 9.3)
EncorafenibApprovedSmall moleculeBRAF V600EPartial signalNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptorPartial signal
NCT01359956: Overall survival, interferon alfa-2b added vs not added to dacarbazine-based chemotherapy (2x2 factorial): HR 0.92 (95% CI 0.70 to 1.20), p=0.68 (Daponte et al., J Transl Med 2013). missed
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT00094653: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone (From randomization until the end of the study, which was defined as the time at which 481 deaths were observed (264 weeks)): Ipilimumab Plus gp100 9.95 months (95% CI 8.48 to 11.5) | gp100 6.44 months (95% CI 5.49 to 8.71)
Lifileucel (Amtagvi)ApprovedCell therapyTumor-infiltrating lymphocytes (polyclonal tumor antigens)not yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02388906: Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09)
NCT01721746: CheckMate 037 coprimaries: objective response rate 31.7% (95% CI 23.5 to 40.8) in the first 120 nivolumab patients vs 10.6% (3.5 to 23.1) with investigator-choice chemotherapy at the interim analysis, reported without a between-group p-value; overall survival median 16 vs 14 months (HR 0.95, 95.54% CI 0.73 to 1.24), no difference (Weber, Lancet Oncol 2015; Larkin, JCO 2018). missed
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
RelatlimabApprovedMonoclonal antibodyLAG-3Reliable signal
NCT03470922: Progression Free Survival (PFS) (From randomization to date of first documented tumor progression or death (up to approximately 33 months)): Arm A: Relatlimab + Nivolumab 10.12 Months (95% CI 6.37 to 15.74) | Arm B: Nivolumab 4.63 Months (95% CI 3.38 to 5.62)
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
TrametinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
VemurafenibApprovedSmall moleculeBRAF (V600 mutant)Partial signalNo reviewed efficacy summary in this indication
Vusolimogene Oderparepvec (Tudriqev)ApprovedOncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
CemiplimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
FianlimabPhase 3Monoclonal antibodyLAG-3not yet gradedNo reviewed efficacy summary in this indication
Intismeran AutogenePhase 3VaccinePatient-specific tumor neoantigens (personalized, up to 34 per patient)not yet gradedNo reviewed efficacy summary in this indication
Tebentafusp-Tebn (KIMMTRAK)Phase 3Protein / enzyme therapeuticgp100-HLA-A*02:01 x CD3Partial signalNo reviewed efficacy summary in this indication
LNS8801Phase 2/3Small moleculeGPER (G protein-coupled estrogen receptor)not yet gradedNo reviewed efficacy summary in this indication
HS-IT101Phase 2Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
VSV-IFNβ-NISPhase 2Oncolytic virusOncolytic VSV expressing interferon-beta and NISnot yet gradedNo reviewed efficacy summary in this indication
EvalstotugPhase 1/2Biologic (subtype unspecified)CTLA-4not yet gradedNo reviewed efficacy summary in this indication
OBX-115Phase 1/2Cell therapyIL-15 receptor signalingnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
NaporafenibDiscontinuedSmall moleculePan-RAFnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Resiquimod to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT06246110 · CT.gov ↗
What to watch
2035 (2)
December 2035 (2)
Phase 2/3MelanomaRecruiting
Est. primary completion 2035-12 · NCT06697301 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2035-12-31 · NCT07365319 · CT.gov ↗

Company guidance: interim data expected second half of 2027 (Eikon Therapeutics, 12 Nov 2026). “We announced the first patient had been dosed in TeLuRide-008 in July 2026 and currently anticipate a first prespecified iDMC interim analysis to select a dose for Part 2 of the trial will take place in the second half of 2027.” Source ↗

What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 May 2026Topline resultEIK1001-005 (NCT06246110) Phase 2 data at ASCO 2026: ORR 63.1%
Eikon Therapeutics · Source ↗